CVS Health (CVS) delivered first quarter 2026 earnings that came in ahead of expectations across all segments. This prompted higher full year earnings guidance and fresh attention on its pharmacy, insurance and technology plans.

The 1-month share price return of 11.68% and 90-day share price return of 11.50% suggest momentum has picked up around the recent earnings beat and raised guidance. The 1-year total shareholder return of 33.46% points to a stronger recovery over time.

If this earnings driven move has you looking beyond a single stock, it could be a good moment to scout other healthcare related opportunities using our screener for 35 healthcare AI stocks

With CVS Health stock up strongly and short term returns outpacing the broader healthcare sector, the key question now is whether recent earnings momentum still leaves room for value or if the market is already pricing in future growth.

Most Popular Narrative: 16% Undervalued

According to the most followed narrative, CVS Health’s fair value of $104.01 sits above the last close at $87.36, which puts the recent earnings beat and guidance upgrade in a different light for long term investors.

By both absolute and relative bases, CVS is undervalued and, therefore, may be viewed as an attractive investment by value-oriented investors who would be more patient and wait for the company to address its temporary problems. The discount of the stock versus its sector peers and estimate of intrinsic value are cited as pointing toward upside potential, assuming that CVS delivers on its cost-cutting initiatives and effectively integrates recent healthcare acquisitions. This could also give CVS an opportunity, if successful, for a re-rating toward a valuation more aligned with the average within its industry segments, which would be expected to create shareholder value.

The narrative focuses on earnings compounding, margin repair and a multi-year cash flow build that connects insurance, pharmacies, clinics and home care. It raises the question of which revenue path, profitability curve and discount rate assumptions link these elements to a triple-digit fair value estimate.

Result: Fair Value of $104.01 (UNDERVALUED)

However, investors still face real risks, including potential execution setbacks related to the US$2b restructuring plan and ongoing pressure from higher medical costs in Health Care Benefits.

Another View: Multiples Paint a Tougher Picture

Not every model points to a wide margin of safety. On current figures, CVS trades on a 38x P/E, compared with a fair ratio of 35.9x and a US Healthcare industry average of 22.1x, while peers sit around 17.9x. That gap suggests investors are paying up, so it may be useful to consider how much room is left if sentiment cools.

Next Steps

The mix of optimism and caution around CVS Health is clear. Use that as a starting point to check the underlying data for yourself and be prepared to act promptly. To weigh up both sides in one place, take a closer look at the 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with a single stock. Use the Simply Wall Street Screener to surface more targeted ideas.

• Boost your hunt for value by scanning companies that combine quality fundamentals with attractive pricing through the 51 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with higher yields and resilient payouts using the 12 dividend fortresses.
• Cut down on unpleasant surprises by filtering for companies with healthier finances via the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.